TY - JOUR
T1 - Bone marrow cell-mediated cardiovascular repair
T2 - potential of combined therapies
AU - Napoli, Claudio
AU - Maione, Ciro
AU - Schiano, Concetta
AU - Fiorito, Carmela
AU - Ignarro, Louis J.
PY - 2007/7
Y1 - 2007/7
N2 - Recent evidence indicates that bone-marrow cells (BMCs) can contribute to the healing process of the injured cardiovascular system via the chemokine receptor CXCR4/SDF-1, thymosin β
4 and integrin α
4β
1 molecular pathways. During tissue ischemia overwhelming numbers of detrimental oxygen radicals are generated, and therefore treatment with antioxidants and L-arginine, the precursor of nitric oxide (NO), could induce beneficial effects beyond those achieved by BMC transplantation alone. Recent studies have reported that BMCs have enhanced neovascularization capacity in cotreatment with α-tocopherol (vitamin E), ascorbic acid (vitamin C) and L-arginine. Moreover, BMC therapy can be combined with gene therapy. Clinical trials employing BMCs in the treatment of cardiovascular diseases have been completed with mixed or positive results, and several trials are ongoing. Here, we discuss the clinical potential of BMC transplantation alone and in combined therapy that aims to restore organ vascularization and function. We also consider the mechanisms of mobilization, differentiation and incorporation of BMCs.
AB - Recent evidence indicates that bone-marrow cells (BMCs) can contribute to the healing process of the injured cardiovascular system via the chemokine receptor CXCR4/SDF-1, thymosin β
4 and integrin α
4β
1 molecular pathways. During tissue ischemia overwhelming numbers of detrimental oxygen radicals are generated, and therefore treatment with antioxidants and L-arginine, the precursor of nitric oxide (NO), could induce beneficial effects beyond those achieved by BMC transplantation alone. Recent studies have reported that BMCs have enhanced neovascularization capacity in cotreatment with α-tocopherol (vitamin E), ascorbic acid (vitamin C) and L-arginine. Moreover, BMC therapy can be combined with gene therapy. Clinical trials employing BMCs in the treatment of cardiovascular diseases have been completed with mixed or positive results, and several trials are ongoing. Here, we discuss the clinical potential of BMC transplantation alone and in combined therapy that aims to restore organ vascularization and function. We also consider the mechanisms of mobilization, differentiation and incorporation of BMCs.
UR - http://www.scopus.com/inward/record.url?scp=34347406145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347406145&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2007.05.004
DO - 10.1016/j.molmed.2007.05.004
M3 - Article
C2 - 17574919
AN - SCOPUS:34347406145
VL - 13
SP - 278
EP - 286
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
SN - 1471-4914
IS - 7
ER -